Meeting
2023 ASCO Genitourinary Cancers Symposium
Full analysis from AVENANCE: A real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC).
Authors
Philippe Barthelemy
Institut de Cancérologie Strasbourg Europe, Strasbourg, France
Philippe Barthelemy , Yohann Loriot , Eric Voog , Jean Christophe Eymard , Alain Ravaud , Aude Flechon , Christine Abraham Jaillon , Matthieu Chasseray , Veronique Lorgis , Werner Hilgers , AurElien Gobert , Sylvestre Le Moulec , Camille Simon , Emanuel Nicolas , Anne Escande , Damien Pouessel , Constant Josse , Marie-Noelle Solbes , Prisca Lambert , Constance Thibault
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Clinical Trial Registration Number
NCT04822350
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 471)
DOI
10.1200/JCO.2023.41.6_suppl.471
Abstract #
471
Poster Bd #
H12
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.
First Author: Srikala S. Sridhar
Poster
2021 ASCO Annual Meeting
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial.
First Author: Thomas Powles
Poster
2021 Genitourinary Cancers Symposium
Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 Japanese subgroup analysis.
First Author: Norihiko Tsuchiya
Poster
2016 Genitourinary Cancers Symposium
COXEN prediction of antineoplastic drug sensitivity in bladder cancer patients.
First Author: Shalin Kothari